Aptevo Therapeutics (NASDAQ:APVO) Posts Earnings Results, Beats Expectations By $0.01 EPS

Aptevo Therapeutics (NASDAQ:APVO) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Fidelity Earnings reports. The business had revenue of $9.01 million for the quarter, compared to the consensus estimate of $8.05 million. Aptevo Therapeutics had a negative net margin of 195.98% and a negative return on equity of 148.97%.

Shares of Aptevo Therapeutics stock traded up $0.04 on Friday, reaching $0.65. The company had a trading volume of 727,500 shares, compared to its average volume of 519,858. The firm’s 50 day moving average price is $0.61 and its two-hundred day moving average price is $0.75. The firm has a market cap of $29.33 million, a PE ratio of -0.27 and a beta of 2.44. Aptevo Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.65. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.21 and a current ratio of 2.63.

A number of research firms have recently issued reports on APVO. Piper Jaffray Companies reduced their price target on shares of Aptevo Therapeutics from $4.50 to $3.00 in a research note on Friday, October 4th. ValuEngine raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 16th.

In other Aptevo Therapeutics news, Director Fuad El-Hibri bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $0.76 per share, with a total value of $76,000.00. Following the purchase, the director now directly owns 1,124,536 shares in the company, valued at $854,647.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 11.74% of the stock is currently owned by insiders.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Recommended Story: Systematic Risk and Investors

Earnings History for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.